Answers are grounded in this paper and cite their sources.
Background KIT alterations occur in distinct melanoma subtypes, yet KIT -mutant melanoma remains clinically and biologically heterogeneous and lacks approved KIT-targeted therapy. We characterized clinico-genomic features of KIT -altered melanoma and described outcomes of patients treated with tyrosine kinase inhibitors (TKI). Methods In this retrospective cohort study, we reviewed 3,837 next-generation sequencing (NGS) reports from the Department of Dermatology, University Hospital Essen (2013-2024) and identified 97 patients with KIT -mutated melanoma. Tumors were classified as KIT hotspot (activating, recurrent variants; n=18) or non-hotspot (n = 79). Clinical characteristics, mutational landscape, number of detected mutations, UV-associated substitution patterns, and survival outcomes were analyzed; five KIT -mutant patients treated with TKIs were described in detail. Results Most cases were of cutaneous (82/97) origin, while other subgroups included mucosal (7/97) and melanoma of unknown primary (8/97). KIT hotspot mutations were enriched in acral and mucosal primaries and were mutually exclusive with BRAF V600 and NRAS Q61/G12 mutations, whereas non-hotspot tumors frequently harbored canonical drivers ( BRAF V600 22.8%, NRAS Q61/G12 17.7%). NF1 mutations were markedly enriched in non-hotspot tumors (62.0% vs 16.7%; p < 0.001). In cutaneous melanoma, non-hotspot mutant tumors showed higher number of mutations than hotspot mutant tumors (median 13 vs 3; p < 0.001) and a more pronounced UV mutation signature. Five patients received TKIs (imatinib, ripretinib, sunitinib, nilotinib) with responses ranging from mixed to complete responses. Conclusions KIT hotspot and non-hotspot variants define biologically distinct subsets of KIT -altered melanoma. Non-hotspot KIT variants frequently co-occur with NF1 -mutations and high-mutation numbers, supporting a passenger role in many cases, whereas hotspot KIT marks a targetable dependency and warrants repeat profiling at progression.
No takes yet. Share an insight, caveat, or question.
Thielmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: